Next Article in Journal
Synthesis, Biological Activity, and Apoptotic Properties of NO-Donor/Enmein-Type ent-Kauranoid Hybrids
Next Article in Special Issue
Dehydroeburicoic Acid from Antrodia camphorata Prevents the Diabetic and Dyslipidemic State via Modulation of Glucose Transporter 4, Peroxisome Proliferator-Activated Receptor α Expression and AMP-Activated Protein Kinase Phosphorylation in High-Fat-Fed Mice
Previous Article in Journal
Cold-Induced Browning Dynamically Alters the Expression Profiles of Inflammatory Adipokines with Tissue Specificity in Mice
Previous Article in Special Issue
One-Pot Three-Component Synthesis of Novel Diethyl((2-oxo-1,2-dihydroquinolin-3-yl)(arylamino)methyl)phosphonate as Potential Anticancer Agents

Prodrug Strategies for Paclitaxel

by 1,2,†, 1,2,†, 1, 1, 2, 1,2,3,*, 1,2,* and 1,2,*
Institution for Advancing Translational Medicine in Bone & Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong 999077, China
Research Group of Precision Medicine and Innovative Drug, HKBU (Hong Kong Baptist University) (Haimen) Institute of Science and Technology, Haimen 226100, China
The State Key Laboratory Base of Novel Functional Materials and Preparation Science, Faculty of Materials Science and Chemical Engineering, Ningbo University, Ningbo 315211, China
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editor: Katalin Prokai-Tatrai
Int. J. Mol. Sci. 2016, 17(5), 796;
Received: 23 March 2016 / Revised: 4 May 2016 / Accepted: 11 May 2016 / Published: 23 May 2016
(This article belongs to the Special Issue Translational Molecular Medicine & Molecular Drug Discovery)
Paclitaxel is an anti-tumor agent with remarkable anti-tumor activity and wide clinical uses. However, it is also faced with various challenges especially for its poor water solubility and low selectivity for the target. To overcome these disadvantages of paclitaxel, approaches using small molecule modifications and macromolecule modifications have been developed by many research groups from all over the world. In this review, we discuss the different strategies especially prodrug strategies that are currently used to make paclitaxel more effective. View Full-Text
Keywords: paclitaxel; poor water solubility; low selectivity; prodrug paclitaxel; poor water solubility; low selectivity; prodrug
Show Figures

Graphical abstract

MDPI and ACS Style

Meng, Z.; Lv, Q.; Lu, J.; Yao, H.; Lv, X.; Jiang, F.; Lu, A.; Zhang, G. Prodrug Strategies for Paclitaxel. Int. J. Mol. Sci. 2016, 17, 796.

AMA Style

Meng Z, Lv Q, Lu J, Yao H, Lv X, Jiang F, Lu A, Zhang G. Prodrug Strategies for Paclitaxel. International Journal of Molecular Sciences. 2016; 17(5):796.

Chicago/Turabian Style

Meng, Ziyuan, Quanxia Lv, Jun Lu, Houzong Yao, Xiaoqing Lv, Feng Jiang, Aiping Lu, and Ge Zhang. 2016. "Prodrug Strategies for Paclitaxel" International Journal of Molecular Sciences 17, no. 5: 796.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop